

LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine+Nevirapine+Zidovudine 150mg+200mg+300mg Tablets *

2. STATEMENT OF ACTIVE SUBSTANCE

Each tablet contains 150 mg lamivudine, 200 mg nevirapine and 300 mg zidovudine.

3. LIST OF EXCIPIENTS

Contains lactose. See patient information leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

60 film-coated tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Oral use
Read the patient information leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP {MM/YYYY}

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C. Protect from light.

* Trade names are not prequalified by WHO. This is under local drug regulatory authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE SUPPLIER

Macleods Pharmaceuticals Limited
304, Atlanta Arcade
Marol Church road
Andheri (East)
Mumbai – 400 059, India.
Tel: +91-22-66762800
Fax: +91 -22-28216599

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA513

13. MANUFACTURER'S BATCH NUMBER

<Batch> {number}

14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE